6 years ago

Divide & Conquer Secures $13.1 Million in Series A to Disrupt Tumor Cell Communication

  • Divide & Conquer, a UK-based biotechnology company, has emerged from stealth with £10m (approximately $13.1m) in Series A financing led by Medicxi

  • The company focuses on glioblastoma, a lethal brain cancer, where cancer cells communicate via tumor microtubes

  • Divide & Conquer aims to disrupt this communication mechanism by leveraging research on cellular parabiosis

  • The founding team includes experts in genetics, neuro-oncology, and venture capital.

      • ProblemHealthcare

      "Glioblastoma, a deadly brain cancer, thrives because cancer cells communicate with each other, making them resistant to treatment. This communication happens through structures called tumour microtubes."

      Solution

      "Divide & Conquer is developing a treatment to disrupt the communication pathways between these cancer cells, effectively cutting off their ability to resist treatment."

      Covered on